The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Evolving role of CELMoDs in multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving role of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma. He highlights the efficacy and tolerability of mezigdomide across combination strategies, including with standard therapies and immunotherapies, as well as emerging data supporting CELMoDs as an important class of oral therapies in relapsed disease. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
